Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: Results of AIDS clinical trials group protocol 315
Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: Results of AIDS clinical trials group protocol 315
复制标题
DOI：
10.1086/515591
复制
发表时间：
1998-07-01
影响因子：
6.4
通讯作者：
Kessler, H
中科院分区：
文献类型：
--
作者：
Lederman, MM;Connick, E;Kessler, H
人类免疫缺陷病毒（HIV）-1感染与进行性细胞介导的免疫缺陷和异常免疫激活有关。尽管高效抗逆转录病毒治疗方案可以增加循环CD 4 T淋巴细胞计数并降低机会性并发症的风险，但这些治疗对免疫重建的影响尚不清楚。在44例中晚期HIV-1感染者中，用齐多夫定、拉米夫定和利托那韦治疗12周后，血浆HIV-1 RNA下降中位数为2.3 log（P
Human immunodeficiency virus (HIV)-1 infection is associated with progressive cell-mediated immune deficiency and abnormal immune activation. Although highly active antiretroviral therapy regimens can increase circulating CD4 T lymphocyte counts and decrease the risk of opportunistic complications, the effects of these treatments on immune reconstitution are not well understood. In 44 persons with moderately advanced HIV-1 infection, after 12 weeks of treatment with zidovudine, lamivudine, and ritonavir, plasma HIV-1 RNA fell a median of 2.3 logs (P